This page will track the quarterly sales of Seattle Genetics' CD30 targeted antibody-drug conjugate ADCETRIS over time. This is net U.S. and Canada sales only and does not include international royalties from Takeda.
Who Am I?
I'm an individual investor from Kansas City. My focus is on biotech stocks, but I enjoy investing in all industries. I'm an old-school, buy and hold investor who believes the best way to outperform and grow capital is to own innovative companies with good management teams over the long-term. more>>>